Secondary Progressive Multiple Sclerosis (SPMS) - Market Insight, Epidemiology and Market Forecast - 2027

Secondary Progressive Multiple Sclerosis (SPMS) - Market Insight, Epidemiology and Market Forecast - 2027

  • Pages: 100
  • Geography: Global
  • Delivery Timeline: 7-10 Business Days
  • Publication: Jan, 2018
  • SKU: DIMI0204
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight's "Secondary Progressive Multiple Sclerosis (SPMS) - Market Insights, Epidemiology and Market Forecast 2027" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2027.
Markets Covered

• United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2016-2027
Secondary Progressive Multiple Sclerosis (SPMS) Understanding and Treatment Algorithm
The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Secondary Progressive Multiple Sclerosis (SPMS) in the US, Europe, and Japan are also provided in the report.
Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology
This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.
Secondary Progressive Multiple Sclerosis (SPMS) Product Profiles & Analysis
This part of the Secondary Progressive Multiple Sclerosis (SPMS) report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.
Secondary Progressive Multiple Sclerosis (SPMS) Market Outlook
The Secondary Progressive Multiple Sclerosis (SPMS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.
Secondary Progressive Multiple Sclerosis (SPMS) Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.
Secondary Progressive Multiple Sclerosis (SPMS) Report Insights

• Patient Population in Secondary Progressive Multiple Sclerosis (SPMS)
• Therapeutic Approaches in Secondary Progressive Multiple Sclerosis (SPMS)
• Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Analysis
• Secondary Progressive Multiple Sclerosis (SPMS) Market Size and Trends
• Secondary Progressive Multiple Sclerosis (SPMS) Market Opportunities
• Impact of upcoming Therapies in Secondary Progressive Multiple Sclerosis (SPMS) Secondary Progressive Multiple Sclerosis (SPMS) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology
Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition Secondary Progressive Multiple Sclerosis (SPMS) Report Assessment
• Current Treatment Practices in Secondary Progressive Multiple Sclerosis (SPMS)
• Unmet Needs in Secondary Progressive Multiple Sclerosis (SPMS)
• Detailed Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Secondary Progressive Multiple Sclerosis (SPMS) market
• Organize sales and marketing efforts by identifying the best opportunities for Secondary Progressive Multiple Sclerosis (SPMS) market
• To understand the future market competition in the Secondary Progressive Multiple Sclerosis (SPMS) market.
1. Report Introduction
2. Secondary Progressive Multiple Sclerosis (SPMS) Market Overview at a Glance
2.1. Market Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) in 2017
2.2. Market Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) in 2027
3. Disease Background and Overview: Secondary Progressive Multiple Sclerosis (SPMS)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
4.3. Total Prevalent Patient Population of Secondary Progressive Multiple Sclerosis (SPMS) in 7MM – By Countries
5. Epidemiology of Secondary Progressive Multiple Sclerosis (SPMS) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.1.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.1.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.1.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.1.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.4.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.4.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.4.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.4.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.5.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.5.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.6.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.6.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.7.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.7.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.8.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.8.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.9.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.9.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Secondary Progressive Multiple Sclerosis (SPMS)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Secondary Progressive Multiple Sclerosis (SPMS)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Secondary Progressive Multiple Sclerosis (SPMS) : 7MM Market Analysis
12.1. 7MM Market Size of Secondary Progressive Multiple Sclerosis (SPMS)
12.2. 7MM Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS)
12.3. 7MM Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products
13. Secondary Progressive Multiple Sclerosis (SPMS) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in United States
13.1.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in United States
13.1.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in Germany
13.2.1.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in Germany
13.2.1.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in France
13.2.2.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in France
13.2.2.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in Italy
13.2.3.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in Italy
13.2.3.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in Spain
13.2.4.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in Spain
13.2.4.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in United Kingdom
13.2.5.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in Japan
13.3.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in Japan
13.3.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2027)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Second